Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $117.6 million.

  • Axsome Therapeutics' Non-Current Debt fell 3464.41% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year decrease of 3464.41%. This contributed to the annual value of $180.7 million for FY2024, which is 148.26% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Non-Current Debt stood at $117.6 million, which was down 3464.41% from $117.5 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Non-Current Debt registered a high of $181.4 million during Q1 2025, and its lowest value of $49.3 million during Q1 2022.
  • Over the past 4 years, Axsome Therapeutics' median Non-Current Debt value was $176.8 million (recorded in 2023), while the average stood at $143.1 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Non-Current Debt skyrocketed by 19934.5% in 2023, and later crashed by 3464.41% in 2025.
  • Axsome Therapeutics' Non-Current Debt (Quarter) stood at $94.3 million in 2022, then surged by 88.92% to $178.1 million in 2023, then rose by 1.48% to $180.7 million in 2024, then plummeted by 34.9% to $117.6 million in 2025.
  • Its last three reported values are $117.6 million in Q3 2025, $117.5 million for Q2 2025, and $181.4 million during Q1 2025.